Tizaro tirzepatide injection: the step-by-step guide

Tirzepatide (Mounjaro) is the only dual GIP and GLP-1 receptor agonist licensed in the UK for weight management, a distinct mechanism from single-pathway GLP-1 medicines.
Each Mounjaro KwikPen contains four weekly doses and is started at the 2.5 mg tolerability dose, titrated upward by your prescriber in approximately four-week steps.
Treatment begins with clinical assessment: tirzepatide is a prescription-only medicine and a registered prescriber must confirm suitability before any injection is given.
Injection sites are the abdomen, outer thigh or upper arm, rotated each week to avoid skin changes at a single spot.

If you've searched for 'tizaro tirzepatide injection', you're likely looking at tirzepatide — the active ingredient in Mounjaro, a once-weekly injection licensed in the UK for weight management. Tirzepatide activates two gut-hormone receptors (GIP and GLP-1) to reduce appetite and slow gastric emptying. It's a prescription-only medicine, so a prescriber must assess suitability before treatment begins. This page walks through how the injection actually works in practice — from picking up your pen to building the habit into everyday life.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

How to inject tirzepatide correctly, from first pen to ongoing routine

Step 1, Before you inject: what to check and prepare

Take your Mounjaro pen out of the fridge around 30 minutes before you plan to inject. Cold medicine straight from the fridge door can sting more; letting it reach room temperature is a small thing that makes a real difference. Check the pen label confirms the correct dose your prescriber has assigned, and look through the viewing window, the liquid should be clear to slightly yellow with no particles. If anything looks off, do not use the pen. Contact your prescriber or the pharmacy.

Choose an injection site: abdomen (at least 5 cm from the navel), outer thigh, or upper arm. Avoid skin that is bruised, tender, hardened or scarred. Clean the spot with an alcohol swab and let it dry fully, injecting through damp skin increases stinging. If you find you're always using the same patch, changing the needle correctly each week and rotating sites both help prevent lipohypertrophy (fatty lumps that reduce absorption).

Wash your hands before you start. That's a step people sometimes skip when they're confident with the process, it still matters every time.

Step 2, The injection itself: what the KwikPen does and what you do

The Mounjaro KwikPen is a pre-filled, pre-set device: you don't draw up a dose or set a dial. Attach a new needle, remove both needle caps, and press the pen firmly against the cleaned skin until you feel it lock. Press and hold the button; you'll hear a click when delivery starts and a second click when it finishes. Keep the pen held in place for about ten seconds after the second click before removing it. This pause matters, removing too quickly can lose part of the dose.

The full injection process for most people takes under a minute once they're familiar with it. For a detailed walkthrough of the pen's mechanics (including what the window shows during delivery) the tirzepatide injection technique guide covers each stage with more detail.

After the injection, dispose of the used needle immediately in a sharps container. Never re-cap a used needle and never place loose needles in household bins.

Step 3, After the injection: what to expect in the early weeks

Gastrointestinal effects are the most commonly reported side effects with tirzepatide: nausea, loose stools, indigestion and reduced appetite are all possible, particularly in the first days after a new dose level. The NHS tirzepatide medicines page sets out the full side-effect profile and advises eating smaller, lower-fat meals as a practical way to ease nausea during the adjustment period. For most people these effects settle within one to two weeks of a new dose.

Injection-site reactions (mild redness or itching) are also reported. Rotating sites each week, as above, helps. If you notice severe stomach pain that spreads to the back, stop the injection and seek urgent medical attention: this is a symptom that needs prompt assessment. The MHRA highlighted acute pancreatitis as a known, infrequent but serious risk with GLP-1 class medicines in a January 2026 Drug Safety Update; any suspected side effect can be reported through the Yellow Card scheme.

Keep your pen stored at 2–8°C between uses. For exact storage windows (including how long it may be kept at room temperature when refrigeration isn't available) the Patient Information Leaflet inside your pack is the definitive reference. Your prescriber can also advise.

Who this injection is licensed for, and the private route

Tirzepatide for weight management is licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. BMI thresholds are adjusted downward for some ethnic backgrounds under UK guidance, your prescriber applies these individually. Tirzepatide also carries a NICE recommendation (TA1026) for NHS access under phased eligibility criteria, though waiting times and qualifying thresholds on the NHS are strict. For anyone exploring what the process actually costs privately, the Mounjaro price comparison page sets out the market context honestly.

Private access through a regulated online pharmacy skips the waiting list but requires the same clinical rigour: a prescriber who holds a GPhC registration must review your health history, verify your identity and weight, and decide suitability before anything is dispensed. If you'd like to read more about how tirzepatide injection works as a treatment, including the mechanism and what to expect across the full course, that page covers the wider clinical picture. For a closer look at the device itself, the tirzepatide pen guide explains how the KwikPen is designed and what makes it straightforward to use at home. At nume, that review is done by a real clinician on the day your consultation is received. There is no algorithm making that call. If you'd like to understand more about what the full treatment journey looks like, the Mounjaro overview covers the wider picture, and our clinical team page explains who reviews every case.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions